Previous 10 | Next 10 |
Gainers: Biofrontera (NASDAQ:BFRI) +14%. Synaptogenix (NASDAQ:SNPX) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Immunic (NASDAQ:IMUX) +10%. Oncternal Therapeutics (NASDAQ:ONCT) +10%. Losers: Sio Gene Therapies (NASDAQ:SIOX) -19%. Anavex Life Sciences (NASDAQ:A...
Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients Scientific manuscript documenting evidence published in Journal of Alzheimer's Disease PR Newswire ...
SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer’s Disease in moderately severe to severe patients. Post-hoc analysis of 95 patients from these two studies with MMSE 10-15, and not taking Namenda, revealed a statistical...
Gainers: Elite Education Group International (NASDAQ:EEIQ) +40%. Bit Digital (NASDAQ:BTBT) +21%. Zeta Global Holdings (NYSE:ZETA) +19%. Synaptogenix (NASDAQ:SNPX) +18%. Marine Petroleum Trust (NASDAQ:MARPS) +16%. Navios Maritime (NYSE:NM) +15%. Biomerica (NASDAQ:BMRA) +13%. Unico Am...
Gainers: Aditxt (NASDAQ:ADTX) +22%, Synaptogenix (NASDAQ:SNPX) +17%, Shineco (NASDAQ:TYHT) +13%, SmileDirectClub (NASDAQ:SDC) +12%, Silverback Therapeutics (NASDAQ:SBTX) +9%. Losers: UpHealth (NYSE:UPH) -34%, Unity Biotechnology (NASDAQ:UBX)...
Futures are up over 0.4% in the pre-market sessions and it looks like it will be a bull’s day today. Futures on the Dow Jones Industrial Average gained 151 points, or 0.47%. S&P 500 futures rose 0.44% while Nasdaq 100 futures added 0.4%. Treasury Secretary Janet Yellen cautioned Tu...
Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference PR Newswire NEW YORK , Sept. 28, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurod...
Few stocks with a market cap above a billion dollars display as much volatility as Cassava Sciences. Their efforts to develop a drug for Alzheimer's patients have recently been met with attacks by short-sellers alleging fraud. There are numerous ways for investors to position them...
Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire NEW YORK , Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics...
Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome - Bryostatin-1 to benefit from previously granted Orphan Drug Status for the treatment of Fragile X syndrome...
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Inc. Company Name:
SNPX Stock Symbol:
OTCMKTS Market:
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery PR Newswire Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways ...